Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial.
Brief Summary: RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as paclitaxel, cyclophosphamide, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether bevacizumab is more effective when given together with paclitaxel or cyclophosphamide and capecitabine in treating patients with breast cancer.

PURPOSE: This randomized phase III trial is studying the side effects of giving bevacizumab together with paclitaxel and to see how well it works compared with giving bevacizumab together with cyclophosphamide and capecitabine as first-line therapy in treating women with locally advanced, recurrent, or metastatic breast cancer.


Options:
A: Arm Label: Arm A: bevacizumab and paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Biological: bevacizumab, Paclitaxel | Arm Label: Arm B: bevacizumab, cyclophosphamide and capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Cyclophosphamide, Capecitabine | Intervention Type: BIOLOGICAL; Name: bevacizumab, Paclitaxel; Assigned to Arm(s): Arm A: bevacizumab and paclitaxel | Intervention Type: BIOLOGICAL; Name: Bevacizumab, Cyclophosphamide, Capecitabine; Assigned to Arm(s): Arm B: bevacizumab, cyclophosphamide and capecitabine
B: Intervention Type: BIOLOGICAL; Name: trastuzumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
C: Arm Label: resp: 4xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: resp: 6xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: nonResp: 4xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: nonResp: 4xNX; Type: EXPERIMENTAL; Interventions: Drug: NX | Intervention Type: DRUG; Name: TAC; Assigned to Arm(s): nonResp: 4xTAC, resp: 4xTAC, resp: 6xTAC | Intervention Type: DRUG; Name: NX; Assigned to Arm(s): nonResp: 4xNX
D: Arm Label: Avastin (bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab [Avastin] | Arm Label: Avastin (bevacizumab) + Xeloda (capecitabine); Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin], Drug: capecitabine [Xeloda] | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): Avastin (bevacizumab), Avastin (bevacizumab) + Xeloda (capecitabine) | Intervention Type: DRUG; Name: capecitabine [Xeloda]; Assigned to Arm(s): Avastin (bevacizumab) + Xeloda (capecitabine)

Answer: A